Thermo-kinetic mixing for pharmaceutical applications
Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
1. A method of making a composite comprising: processing one or more active pharmaceutical ingredients (APIs) having an immiscible crystalline or intermediate morphology with one or more pharmaceutically acceptable excipients by thermokinetic compounding, wherein the processing renders the API amorphous, and the amorphous character of the API improves the miscibility of the API and the excipients and the dissolution rate of the composite as compared to thermally processing the crystalline or intermediate morphology API with the excipients by a process other than thermokinetic compounding.
2. The method of claim 1 , wherein one or more pharmaceutically acceptable excipients is a polymer having a high melt viscosity.
3. The method of claim 2 , wherein the polymer is a cellulose derivative.
4. The method of claim 3 , wherein the cellulose derivative is selected from the group consisting of methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate trimellate, hydroxypropyl methylcellulose phthalate, and cellulose acetate butyrate.
5. The method of claim 2 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidones, polyacrylates, polymethacrylates, polyvinyl alcohols, polyethylene glycols, polyvinyl acetate polyvinylpyrrolidone copolymers, polyethylene oxides, dimethylaminoethyl methacrylate-methacrylic acid ester copolymers, ethylacrylate-methylmethacrylate copolymers, poly(methacrylate ethylacrylate) copolymers, poly(methacrylate methylmethacrylate) copolymers, starches, pectins, polysaccharides, gum arabic, guar gum, and xanthan gum.
6. The method of claim 1 , wherein one or more pharmaceutically acceptable excipients is a crystalline or semi-crystalline pharmaceutically acceptable polymer.
7. The method of claim 1 , wherein at least one API is thermally labile.
8. The method of claim 1 , wherein at least one API is poorly water-soluble.
9. The method of claim 1 , wherein the unprocessed API has a crystalline morphology.
10. The method of claim 1 , wherein the unprocessed API has an intermediate morphology.
11. The method of claim 1 , wherein the amorphous API has at least about 94% drug potency as compared to the unprocessed API having an immiscible crystalline or intermediate morphology.
12. The method of claim 1 , wherein the composite processed by thermokinetic compounding does not comprise a processing agent.
13. The method of claim 1 , wherein the composite processed by thermokinetic compounding is a single phase, amorphous composite.
14. The method of claim 13 , wherein the composite is formulated for immediate release, delayed release, controlled release, or extended release.
15. The method of claim 1 , wherein the composite processed by thermokinetic compounding is a single phase, miscible composite.
16. The method of claim 15 , wherein the composite is formulated for immediate release, delayed release, controlled release, or extended release.